Analysts who follow Lexicon Pharmaceuticals, Inc. (LXRX) on average expect it to climb 98.10% over the next twelve months. Those same analysts give the stock an average rating of Buy.
That average rating earns Lexicon Pharmaceuticals, Inc. an Analyst Ranking of 24, which means it ranks higher than 24 of stocks, based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With Lexicon Pharmaceuticals, Inc. Stock Today?
Lexicon Pharmaceuticals, Inc. (LXRX) stock is trading at $2.00 as of 10:10 AM on Tuesday, Jun 30, a rise of $0.02, or 1.01% from the previous closing price of $1.98. The stock has traded between $1.97 and $2.02 so far today. Volume today is less active than usual. So far 63,342 shares have traded compared to average volume of 969,947 shares.
